Generating local amyloidosis in mice by the subcutaneous injection of human insulin amyloid fibrils

MARYAM CHINISAZ1, AZADEH Ebrahim-Habibi2,3, PARICHEHREH YAGHMAEI1, KAZEM PARIVAR1 and AHMAD-REZA DEHPOUR4

1Department of Biology, Science and Research Branch, Islamic Azad University; 2Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences; 3Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences; 4Department of Pharmacology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Received January 1, 2014; Accepted May 16, 2014

DOI: 10.3892/etm.2014.1772

Abstract. Localized deposits of amyloid structures are observed in various pathological conditions. One example of when local amyloidosis occurs is following repeated insulin injections in diabetic patients. The present study aimed to simulate the same condition in mice. To obtain the amyloid structures, regular insulin was incubated at 57˚C for 24 h. The subsequently formed amyloid fibrils were analyzed using the Congo red absorbance test, as well as transmission electron microscopy images, and then injected into mice once per day for 21 consecutive days. Firm waxy masses were developed following this period, which were excised, prepared as thin sections and stained with haematoxylin and eosin, Congo red and Sudan black. Histological examination revealed that these masses contained adipose cells and connective tissue, in which amyloid deposition was visible. Thus, localized amyloidosis was obtained by the subcutaneous injection of insulin fibrils. The present results may be of further use in the development of models of amyloid tumors.

Introduction

Amyloidosis refers to the extracellular accumulation of amyloid fibrils in various tissues and organs, which may result in the disruption of their function. Amyloid fibrils are a specific type of protein aggregate which, upon deposition in particular tissues, may cause serious illness that is often fatal when major organs are involved, or when the amyloidosis is systemic (1,2).

Amyloid tumors, in contrast to systemic amyloidosis, are localized deposits that are usually accompanied by mild clinical symptoms (3). The presence of these deposits has been reported in a number of anatomical sites, including the orbit, neck, oral cavity, breasts, heart, liver and nervous system (3,4). Common clinical conditions associated with amyloid tumors are long-term hemodialysis, chronic inflammation and infections, including tuberculosis and osteomyelitis. Occasionally, patients have been reported to have amyloid deposits in the soft tissue (5), bladder (6) or the respiratory (7) and gastrointestinal tracts (8) without clinical symptoms.

Diabetes mellitus is a highly prevalent illness and a number of diabetic patients require treatment with subcutaneous insulin injections. A previous study demonstrated that insulin injections are associated with local amyloidosis (9). Usually, these are case reports of patients who have detected an abnormal mass in the injection site (10-12). From these studies, it may be hypothesized that amyloidosis may be observed regardless of the location of the injection (13). For example, insulin amyloids have been observed in the shoulders (2), arm (14) and abdominal walls (14-16), and frequently in the areas surrounding the injection site. The formation of insulin fibrils occurs regardless of the source (14) and type (10,11) of insulin administered.

During the course of studying amyloid formation and its prevention, in vitro tests on the potential toxicity of amyloid fibrils and associated structures are usually performed on cells (17,18) or organelles (19). The subsequent step to this would be experiments on laboratory animals that are models of the specific amyloid-related disease (for example Alzheimer's disease) (20-23). However, to the best of our knowledge, an animal model for local amyloidosis has not yet been presented. The method established in the present study may be used as a general representation of local amyloidosis, in a similar manner to the use of the in vitro fibril formation of model proteins, as an indicator of the behavior of pathogenic proteins.

Materials and methods

Animals. Eight male NMRI mice weighing 26-28 g (average weight 27 g) were obtained from the Pasteur Institute of Tehran (Tehran, Iran) and acclimatized to the new location for
All animals were housed under standard conditions with a 12 h dark/light cycle, 50% humidity, a temperature of 22±2°C and free access to water and food (standard pellet feed). The present study was approved by the Animal Ethics Committee of the Science and Research Branch at the Islamic Azad University (Tehran, Iran).

Amyloid preparation. Regular insulin (EXIR Pharmaceutical Co., Tehran, Iran) was diluted in 50 mM phosphate buffer (pH 7.4) to 0.5 mg/ml. It was incubated at 57°C for 24 h whilst being stirred by Teflon magnetic bars. To confirm the amyloid fibril formation of regular insulin, a Congo red absorbance assay was performed according to a previously described method (24). Images captured under a transmission electron microscopy (TEM; CEM 902A Zeiss microscope; Carl Zeiss, Jena, Germany) were also used as complementary proof. The Congo red kit was obtained from Sigma-Aldrich (St. Louis, MO, USA).

Experimental groups. Eight mice were randomly divided into two groups (n=4). The first group (control) received daily injections of phosphate buffer (an insulin amyloid vehicle) for 21 consecutive days. The second group (experimental) received daily injections of amyloid fibrils (113 µl) subcutaneously for 21 consecutive days. All groups received their normal diet during the experimental period.

Histological processing. After 21 days, the waxy masses were excised. Tissue sections were embedded in paraffin and hematoxylin and eosin (H&E), as well as Congo red and Sudan black staining, were applied to each tissue block. A light microscope (Carl Zeiss AG, Oberkochen, Germany) was used to observe the tissue section.

Results

Model development. The in vitro incubation of insulin under amyloidogenic conditions resulted in the formation of insulin fibrils. The shift observed in the absorption spectrum of Congo red (Fig. 1), along with the TEM images indicating the presence of distinct fibrils, were taken as validation of insulin amyloid formation. The pre-formed amyloids were subsequently injected into the mice.

Tumor formation. After 21 days, no abnormalities in appearance around the injection site were observed in the control group. An abnormal mass was detected in all mice in the experimental group. Two mice from the experimental group were randomly selected, and a biopsy was performed. The masses formed upon amyloid injection were waxy bodies of a white-yellow color and a size of ~10x10x2 mm³. The masses appeared similar to the areas of lipohypertrophy observed in human diabetic cases as previously reported (9,25).

Tissue staining and analysis. Upon microscopic investigation of the tissues, localized amyloid fibrils surrounded by connective tissue were detected following H&E staining (Fig. 2). Congo red staining was also performed (Fig. 3), since it is a specific stain for the detection of amyloid structures (24). Sudan black staining confirmed that the excised tissue included adipose tissue (Fig. 3). Based on these results, it was concluded that an amyloid tumor containing fibrillar deposits was formed at the injection site of the two mice.

Discussion

More than 20 proteins and 24 protein precursors that are able to form amyloid fibrils in a comparable manner have been reported (26,27). In vivo, the deposition of these fibrils in the extracellular environment results in amyloidosis (28). Usually, soluble proteins become insoluble and are deposited as protein aggregates which then develop into amyloids (29,30). There are various types of amyloidosis which, in general, may be classified as primary (AL) and secondary (AA). AL amyloidosis is related to the deposition of immunoglobulin light chains. AA amyloidosis occurs with chronic disease, especially when an inflammatory process is present (2,12,31). The disease may influence several organs, or may be limited to a particular organ. Symptoms related to amyloidosis depend on the organ involved (32,33).

The skin may become involved with amyloidosis at various levels. Primary cutaneous amyloidosis occurs as nodular,
macular and lichen (or papular) amyloidosis (33,34). In the latter two types, amyloid fibrils accumulate in the papillary dermis. An uncommon form of amyloidosis may affect the subcutis, dermis and vascular walls, causing local plasma cell dyscrasia (35,36). Nodular amyloidosis has a higher relapse rate compared with the other forms. The development of local cutaneous disease to a systemic form is rare, but has been reported for nodular amyloidosis (37,38). To the best of our knowledge, no specific therapeutic treatments currently exist for skin amyloidosis and surgical excision is the routine treatment. The method that has been reported in the present study may be expanded and used to test potential treatments for these conditions.

In diabetic patients, a cutaneous amyloid tumor may form at the site of insulin injection (11,25). Within the tumor, lipohypertrophy, which includes the amyloid fibrils, is usually present (11,25). The results of the current study are in accordance with this type of physiopathological finding. From 1983, incidences of amyloidosis in insulin injection sites have been reported in rats (11).

As previously mentioned, there are a limited number of published case reports about cutaneous amyloidosis caused by repeated subcutaneous insulin administration (2,15,14). A limited number of studies have associated cutaneous amyloidosis with non-human insulin, such as porcine insulin, and there are even fewer published studies investigating amyloidosis with human insulin (2,16).

One form of cutaneous amyloidosis is related to local subcutaneous injections of insulin, the incidence rate of which may be underestimated when considering the high prevalence of diabetes mellitus and insulin treatment. The simple method proposed in the present study may be useful in investigating the characteristics of local amyloidosis, as well in the search for potential treatments. The exact mechanism by which insulin-induced amyloidosis occurs remains largely unknown in the scientific literature. Notably, in previous studies, insulin itself was observed to have properties of lipohypertrophy, while the present study used injections of insulin amyloid fibrils and observed the same effect. It has been verified that long-term
injection of insulin may result in lipohypertrophy, lipatrophy and, rarely, infection (25). Further tests are required to ascerta

tion whether insulin amyloid injection may cause the same effects. Another use for the method established in the current study may be to investigate the tendency of various insulin types to cause amyloidosis. Finally, irrespective of the amyloidosis type, the present method may be used to further study local amyloidosis.

Acknowledgements

The authors thank those who assisted in carrying out this study, particularly Dr Aidin Dilmaghanian for providing their valuable assistance with regard to the study, and Drs J. Kheirkhah, B. J. J. and M. A. Theaker for their assistance in the preparation of the manuscript. The authors thank those who assisted in carrying out experiments, particularly Dr Aidin Dilmaghanian for providing

References

1. Husby G: Amyloidosis and rheumatoid arthritis. Clin Exp Rheumatology 3: 173–180, 1985.
2. Sahoo S, Reeves W and DeMay RM: Amyloid tumor: a clinical and cytomorphic study. Diagn Cytopathol 28: 325–328, 2003.
3. Aono J, Yamagata K and Yoshida H: Local amyloidosis in the hard palate: a case report. Oral Maxillofac Surg 13: 119–122, 2009.
4. Weiss SW and Goldblum JR: Enzinger and Weiss's Soft Tissue Tumors. 4th edition. Mosby Elsevier, Philadelphia, PA, USA, 2008.
5. Krishnan J, Chu WS, Elrod JP and Frizzera G: Tumoral presentation of amyloidosis (amyloidomas) in soft tissues. A report of 14 cases. Am J Clin Pathol 100: 135–144, 1993.
6. Khan SM, Birj P.J, Bass PS, Williams JH and Theaker JM: Localized amyloidosis of the lower genitourinary tract: a clinicopathological and immunohistochemical study of nine cases. Histopathology 21: 143–147, 1992.
7. Ihling C, Weirich G, Gua A and Schafer H: Amyloidosis of the lung - an immunocytoma? Pathol Res Pract 192: 446–452, 1996.
8. Deans GT, Hale RJ, McMahon RF and Brough WA: Amyloid tumour of the colon. J Clin Pathol 48: 592–593, 1995.
9. Sie MP, van der Wiel HE, Snieds FM and de Boer AC: Human recombinant insulin and amyloidosis: an unexpected association. Neth J Med 68: 138–140, 2010.
10. Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, Rennie JA, Gilbey SG and Watkins PJ: Insulin as an amyloid fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 31: 158–161, 1988.
11. Störrkel S, Schneider HM, Münterling H and Kashwagi S: Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest 48: 108–111, 1983.
12. Swift B: Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med 19: 881–882, 2002.
13. Muzaaffar M and Ahmad A: The mechanism of enhanced insulin amyloid fibril formation by NaCl is better explained by a conformational change model. PloS One, 6: e27906, 2011.
14. Yumulu S, Barany R, Eriksson M and Röcken C: Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. Hum Pathol 40: 1655–1660, 2009.
15. Albert SG, Obadiah J, Parseghian SA, Yadira Hurley M and Mooradian AD: Severe insulin resistance associated with subcutaneous amyloid deposition. Diabetes Res Clin Pract 75: 374–376, 2007.
16. Shikama Y, Kizawa Y, Yagishita N, Uehara O, Murata Y, Yajima N, Wada R and Yajishita S: Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med 49: 397–401, 2010.
17. El-Agnaf OM, Jakos R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D and Wallace A: Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS letters 440: 71–75, 1998.
18. Hertel C, Hauser N, Subbenel R, Seiheimer B and Kemp JA: β-amyloid-induced cell toxicity: enhancement of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-negative cell death. Neurochem Res 37: 227–256, 2012.
19. Meratan AA, Ghasemi A and Nemat-Gorgani M: Membrane integrity and amyloid cytotoxicity: a model study involving mitochondria and lsozone fibrillation products. J Mol Biol 409: 826–838, 2011.
20. Maurice T, Lockhart BP and Privat A: Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181–193, 1996.
21. Morimoto K, Yoshiki K, Tonohiro T, Yamada N, Oda T and Kaneko I: Co-injection of β-amyloid with ibotenic acid induces synergistic loss of rat hippocampal cells. Neuroscience 84: 487–497, 1998.
22. Pieramartiri TC, Varensen-Filho S, de Araújo Herculino B, Martins WC, Dal'agnolo D, Stroeh E, Carqueja CL, Boeck CR and Tasca CI: Atorvastatin prevents hippocampal cell death due to quinoline acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. Neurotox Res 16: 106–115, 2009.
23. Prediger RD, Franco J.L., Pandolfo P, Medeiros R, Duarte F.S, Di Giunta G, Figueiredo CP, Farina M, Calixto JB, Takahashi RN and Dafre AL: Differential susceptibility following β-amyloid peptide-(1–40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response. Behav Brain Res 177: 205–213, 2007.
24. Klunk WE, Pettegrew J and Abraham DJ: Quantitative evaluation of congo red binding to amyloid-like proteins with a β-pleated sheet conformation. J Histochem Cytochem 37: 1273–1281, 1989.
25. Wallymahmed ME, Littler P, Clegg C, Haqanni MT and Macfarlane IA: Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections: a cause of poor diabetic control. Postgrad Med J 80: 732–733, 2004.
26. Westermark P, Araki S, Benson MD, Cohen AS, Frangione B, Masters CL, Saraiva MJ, Sipe JD, Husby G, Kyle RA and Selkoe D: Nomenclature of amyloid fibril proteins: Report from the meeting of the International Nomenclature Committee on Amyloidosis, August 8–9, 1998. Part 1: Amyloid 6: 63–66, 1999.
27. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlina G, Saraiva MJ and Sipe JD: Amyloid fibril protein nomenclature - 2002. Amyloid 9: 197–200, 2002.
28. Cortés A: Primary cutaneous amyloidosis. Dermatologica 139: 109–114, 1969.
29. Kumar V, Abbas AK, Fausto N and Aster JC (eds): Robbins and Cotran Pathologic Basis of Disease. 8th edition. Saunders Elsevier, Philadelphia, PA, USA, 2010.
30. Rooban T, Sasawathi T, Al Zainah FB, Devi U, Elbighat B and Ranganathan K: A light microscopic study of fibrosis involving muscle in oral submucous fibrosis. Indian J Dent Res 16: 131–134, 2005.
31. Lasagna-Reeves CA, Clos AL, Moidoro-Hiruiti T, Goldblum RM, Jackson GR and Kayed R: Insulated insulin forms toxic pulmonary amyloid aggregates. Endocrinology 151: 4717–4724, 2010.
32. Hazenberg BP, van Gamenen II, Bijzet J, Jager PL and van Rijswijk MJ: Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med 62: 121–128, 2010.
33. Yamamoto T: Amyloidosis in the skin. In: Amyloidosis - an Insight to Disease of Systems and Novel Therapies. Güvenç IA (ed). InTech, Rijeka, Croatia, pp91–104, 2011.
34. Touart DM and Sau P: Cutaneous disease process. In: The Acam Dermatol 39: 149–171, 1998.
35. Moon AO. Calamia KT and Walsh JS: Nodular amyloidosis: review and long-term follow-up of 16 cases. Arch Dermatol 139: 1157–1159, 2003.
36. Woollons A and Black MM: Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol 145: 105–109, 2001.